- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05247203
Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus
December 5, 2023 updated by: RemeGen Co., Ltd.
A Phase I, Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Telitacicept in Chinese Subjects With Systemic Lupus Erythematosus (SLE)
This is a multi-center, open-label, phase I study.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to evaluate the pharmacokinetics, safety and efficacy of Telitacicept in Chinese patients with systemic lupus erythematosus.
Study Type
Interventional
Enrollment (Actual)
92
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Anhui
-
Bengbu, Anhui, China, 233004
- The First Affiliated Hospital of Bengbu Medical College
-
Hefei, Anhui, China, 230001
- The First Affiliated Hospital of University of Science and Technology of China
-
-
Beijing
-
Beijing, Beijing, China, 100032
- Peking Union Medical College Hospital
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510260
- The second Affiliated Hospital of Guangzhou Medical University
-
-
Guangxi
-
Guilin, Guangxi, China, 541001
- Affiliated Hospital of Guilin Medical University
-
-
Hebei
-
Baoding, Hebei, China, 071000
- Affiliated Hospital of Hebei University
-
Shijiazhuang, Hebei, China, 050000
- The Second Hospital of Hebei Medical University
-
-
Hunan
-
Changsha, Hunan, China, 410011
- The Second Xiangya Hospital of Central South University
-
Changsha, Hunan, China, 410008
- Xiangya Hospital, Central South University
-
-
Liaoning
-
Shenyang, Liaoning, China, 110001
- The First Hospital of China Medical University
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710061
- The First Affiliated Hospital of Xi'an Jiaotong University
-
-
Shandong
-
Jinan, Shandong, China, 250012
- Qilu Hospital of Shandong University
-
Yantai, Shandong, China, 264200
- Yantai Yuhuangding Hospital
-
-
Shanxi
-
Taiyuan, Shanxi, China, 030032
- Shanxi Bethune Hospital
-
Taiyuan, Shanxi, China, 030001
- The Second Hospital of Shanxi Medical University
-
-
Tianjin
-
Tianjin, Tianjin, China, 300052
- General Hospital of Tianjin Medical University
-
-
Xinjiang
-
Ürümqi, Xinjiang, China, 830001
- The People's hospital of Xinjiang Uygur Autonomous Region
-
-
Yunnan
-
Kunming, Yunnan, China, 650011
- The First People's Hospital of Yunnan Province
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310009
- The second affiliated hospital of Zhejiang University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Subjects who give consent to this study participation and sign informed consent form;
- Males and females, between the ages of 18 and 65 years old, inclusive, at the screening visit;
- Diagnosis of SLE as defined by the American College of Rheumatology (ACR) 1997 criteria, with 4 or more of the 11 ACR criteria present;
- SELENA-SLEDAI score ≥8 points with a clinical SELENA-SLEDAI score ≥6 points if low complement levels and/or anti-ds-DNA antibodies are present at the screening visit;
- Subjects with unequivocally positive test for anti-nuclear antibody (ANA) and/or anti-ds-DNA serum antibody;
- Be on a SLE standard treatment regimen (and remain stable) for a period of at least 30 days prior to Day 0. The standard regimen consists of the following medication(s) (alone or in combination):corticosteroids, anti-malarials, non-steroidal anti-inflammatory drugs (NSAIDs), other immunosuppressive or immunomodulatory agents including azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, leflunomide, tacrolimus, cyclosporine.
Exclusion Criteria:
- Subjects with severe lupus kidney disease (defined by proteinuria >6g/24h or serum creatinine >2.5mg/dL or serum creatinine >221μmol/L) or active nephritis requiring prohibited medications, or subjects requiring hemodialysis or prednisone (or its equivalent)≥100mg/d for a period of ≥14 days within 8 weeks of Day 0;
- Central nervous system (CNS) disease associated with lupus or not [including seizures, psychosis, organic brain syndrome, cerebrovascular accident (CVA), encephalitis, CNS angiitis] within 8 weeks prior to the screening visit;
Laboratory abnormalities including, but not limited to the following:
- ALT/AST≥2×upper limit of normal (ULN);
- endogenous creatinine clearance rate<30 mL/min;
- white blood cell count<2.5×10^9/L;
- hemoglobin<85 g/L;
- platelet count<50×10^9/L;
- Active hepatitis or a history of severe liver disease at the screening visit. Positive test for Hepatitis B surface antigen (HBsAg) or anti-hepatitis C virus antibodies (HCVAb). If anti-HBcAb result is positive while HBsAg result is negative, hepatitis B virus (HBV)-(DNA) test will be performed. If HBV-DNA result is negative, the patient is eligible;
- Subjects with immunodeficiency, uncontrolled severe infection or active/recurrent gastrointestinal ulcers;
- Pregnant or lactating female subjects or sexually active subjects who refuse to practice the protocol-specified contraception throughout the study;
- History of allergy to humanized biological products;
- Subjects who received live vaccine within 28 days of Day 0;
- Participation in any other investigational study drug trial in the past 28 days or 5 half-lives, whichever was longer, prior to Day 0. Subjects who participated in a clinical trial on B-cell-targeted drug, or tumor necrosis factor inhibitor, or interleukin receptor blocker within 12 months prior to Day 0 would be excluded;
- Subjects who received other B-cell targeted drugs, such as Belimumab, rituximab or Epratuzumab within 12 months prior to Day 0;
- Subjects who received tumor necrosis factor inhibitors, interleukin receptor blockers within 12 months prior to Day 0;
- Subjects who received intravenous immune globulin (IVIG), or high dose prednisone or its equivalents (≥100mg/d) for a period of ≥ 14 days, or plasma exchange within 28 days prior to Day 0;
- Subjects who received IL-2, Thalidomide, Tripterygium wilfordii or Chinese medicinal preparations containing Tripterygium wilfordii within 28 days prior to Day 0;
- Subjects with active infections (herpes zoster, HIV infection, active tuberculosis, etc.) at the screening visit;
- Subjects with depression or suicidal thoughts;
- Any condition or circumstance that, in the opinion of the investigator, may compromise the patient's ability to comply with the study protocol..
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Telitacicept Arm 1
Telitacicept 80mg, once a week for 24 weeks plus standard therapy
|
subcutaneous injection
Other Names:
A standard regimen consists of the following medication(s) (alone or in combination):corticosteroids, anti-malarials, non-steroidal anti-inflammatory drugs (NSAIDs), other immunosuppressive or immunomodulatory agents including azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, leflunomide, tacrolimus, cyclosporine.
|
Experimental: Telitacicept Arm 2
Telitacicept 160mg, once a week for 24 weeks plus standard therapy
|
subcutaneous injection
Other Names:
A standard regimen consists of the following medication(s) (alone or in combination):corticosteroids, anti-malarials, non-steroidal anti-inflammatory drugs (NSAIDs), other immunosuppressive or immunomodulatory agents including azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, leflunomide, tacrolimus, cyclosporine.
|
Experimental: Telitacicept Arm 3
Telitacicept 160mg, once a week for 12 weeks followed by once every two weeks for another 12 weeks plus standard therapy
|
subcutaneous injection
Other Names:
A standard regimen consists of the following medication(s) (alone or in combination):corticosteroids, anti-malarials, non-steroidal anti-inflammatory drugs (NSAIDs), other immunosuppressive or immunomodulatory agents including azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, leflunomide, tacrolimus, cyclosporine.
|
Experimental: Telitacicept Arm 4
Telitacicept 240mg, once a week for 24 weeks plus standard therapy
|
subcutaneous injection
Other Names:
A standard regimen consists of the following medication(s) (alone or in combination):corticosteroids, anti-malarials, non-steroidal anti-inflammatory drugs (NSAIDs), other immunosuppressive or immunomodulatory agents including azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, leflunomide, tacrolimus, cyclosporine.
|
Experimental: Telitacicept Arm 5
Telitacicept 240mg, once every two weeks for 24 weeks plus standard therapy
|
subcutaneous injection
Other Names:
A standard regimen consists of the following medication(s) (alone or in combination):corticosteroids, anti-malarials, non-steroidal anti-inflammatory drugs (NSAIDs), other immunosuppressive or immunomodulatory agents including azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, leflunomide, tacrolimus, cyclosporine.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Peak plasma concentration (Cmax) of Telitacicept
Time Frame: up to 42 days following the last dose of Telitacicept
|
Cmax is defined as peak plasma concentration of Telitacicept
|
up to 42 days following the last dose of Telitacicept
|
Time to reach Cmax (tmax) of Telitacicept
Time Frame: up to 42 days following the last dose of Telitacicept
|
tmax is defined as time to reach Cmax of Telitacicept
|
up to 42 days following the last dose of Telitacicept
|
Observed plasma concentration of Telitacicept just prior to the beginning of a dosing interval (Ctrough)
Time Frame: up to 42 days following the last dose of Telitacicept
|
Ctrough is defined as observed plasma concentration of Telitacicept just prior to the beginning of a dosing interval
|
up to 42 days following the last dose of Telitacicept
|
Average concentration (Cav) of Telitacicept
Time Frame: up to 42 days following the last dose of Telitacicept
|
Average concentration of Telitacicept
|
up to 42 days following the last dose of Telitacicept
|
Area under the curve from time zero to last quantifiable concentration (AUC 0-t) of Telitacicept
Time Frame: up to 42 days following the last dose of Telitacicept
|
AUC 0-t is defined as area under the curve from time zero to last quantifiable concentration of Telitacicept
|
up to 42 days following the last dose of Telitacicept
|
Area under the curve from time zero to tau (AUC 0-tau) of Telitacicept
Time Frame: up to 42 days following the last dose of Telitacicept
|
AUC 0-tau is defined as area under the curve from time zero to tau of Telitacicept
|
up to 42 days following the last dose of Telitacicept
|
Terminal elimination rate constant (λz) of Telitacicept
Time Frame: up to 42 days following the last dose of Telitacicept
|
λz is defined as terminal elimination rate constant
|
up to 42 days following the last dose of Telitacicept
|
Terminal elimination half-life (t1/2z) of Telitacicept
Time Frame: up to 42 days following the last dose of Telitacicept
|
t1/2z is defined as terminal elimination half-life of Telitacicept
|
up to 42 days following the last dose of Telitacicept
|
Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F) of Telitacicept
Time Frame: up to 42 days following the last dose of Telitacicept
|
Vz/F is defined as apparent volume of distribution during the terminal phase after extravascular administration of Telitacicept
|
up to 42 days following the last dose of Telitacicept
|
Apparent total body clearance of drug from plasma after extravascular administration (CL/F) of Telitacicept
Time Frame: up to 42 days following the last dose of Telitacicept
|
CL/F is defined as apparent total body clearance of drug from plasma after extravascular administration of Telitacicept
|
up to 42 days following the last dose of Telitacicept
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of participants achieving a SLE Responder Index (SRI)
Time Frame: Week 4, 8, 12, 16, 20, and 24
|
Percentage of subjects with a ≥ 4 point reduction from baseline in SELENA-SLEDAI score, and no worsening (increase of < 0.30 points from baseline) in PGA, and no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with baseline.
|
Week 4, 8, 12, 16, 20, and 24
|
Percentage of participants achieving a SELENA-SLEDAI improvement of ≥4 points
Time Frame: Week 4, 8, 12, 16, 20, and 24
|
SELENA-SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105.
|
Week 4, 8, 12, 16, 20, and 24
|
Change From Baseline to W24 in patient global assessment (PGA)
Time Frame: Week 4, 8, 12, 16, 20, and 24
|
PGA is a visual analog scale scored from 0 to 3 (1=mild, 2=moderate, 3=severe).
|
Week 4, 8, 12, 16, 20, and 24
|
Change From Baseline to W24 in IgG
Time Frame: Week 4, 8, 12, 16, 20, and 24
|
Immunoglobulins (IgG, IgA and IgM) are proteins produced by plasma cells.
|
Week 4, 8, 12, 16, 20, and 24
|
Change From Baseline to W24 in IgA
Time Frame: Week 4, 8, 12, 16, 20, and 24
|
Immunoglobulins (IgG, IgA and IgM) are proteins produced by plasma cells.
|
Week 4, 8, 12, 16, 20, and 24
|
Change From Baseline to W24 in IgM
Time Frame: Week 4, 8, 12, 16, 20, and 24
|
Immunoglobulins (IgG, IgA and IgM) are proteins produced by plasma cells.
|
Week 4, 8, 12, 16, 20, and 24
|
Change From Baseline to W24 in C3
Time Frame: Week 4, 8, 12, 16, 20, and 24
|
Complement (C3/C4) are proteins that are part of the immune system.
|
Week 4, 8, 12, 16, 20, and 24
|
Change From Baseline to W24 in C4
Time Frame: Week 4, 8, 12, 16, 20, and 24
|
Complement (C3/C4) are proteins that are part of the immune system.
|
Week 4, 8, 12, 16, 20, and 24
|
Number of Participants Experiencing Adverse Events (AEs)
Time Frame: up to 28 days following the last dose of Telitacicept
|
Adverse event means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related.
|
up to 28 days following the last dose of Telitacicept
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 11, 2022
Primary Completion (Actual)
October 25, 2023
Study Completion (Actual)
November 13, 2023
Study Registration Dates
First Submitted
January 26, 2022
First Submitted That Met QC Criteria
February 9, 2022
First Posted (Actual)
February 18, 2022
Study Record Updates
Last Update Posted (Estimated)
December 6, 2023
Last Update Submitted That Met QC Criteria
December 5, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18C020
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Lupus Erythematosus
-
SanofiCompletedCutaneous Lupus Erythematosus-Systemic Lupus ErythematosusJapan
-
Kyowa Kirin Co., Ltd.RecruitingHealthy Volunteers | Systemic Lupus Erythematosus (SLE) | Cutaneous Lupus Erythematosus (CLE)Japan
-
Second Xiangya Hospital of Central South UniversityNational Natural Science Foundation of China; Hunan Provincial Natural Science... and other collaboratorsActive, not recruitingCutaneous Lupus Erythematosus | Systemic Lupus Erythematosus RashChina
-
University Hospital, BrestRecruitingSystemic Lupus Erythematosus (SLE)France
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingSystemic Lupus Erythematosus, SLEChina
-
TJ Biopharma Co., Ltd.TerminatedSystemic Lupus Erythematosus (SLE)China
-
AstraZenecaActive, not recruitingActive Systemic Lupus ErythematosusThailand, Korea, Republic of, Philippines, China, Taiwan, Hong Kong
-
Novartis PharmaceuticalsActive, not recruitingSystemic Lupus Erythematosus (SLE)Hungary, Spain, Germany, Israel, Thailand, France, Russian Federation, China, Japan, Taiwan, Korea, Republic of, Poland, Australia, Argentina, Czechia
-
AstraZenecaPRA Health SciencesCompletedActive Systemic Lupus ErythematosusUnited States, France, Germany, Spain, Belgium, Russian Federation, Japan, Korea, Republic of, Argentina, Bulgaria, South Africa, Mexico, Canada, Brazil, Lithuania
-
Novartis PharmaceuticalsNot yet recruitingSystemic Lupus Erythematosus, SLE
Clinical Trials on Telitacicept
-
The Children's Hospital of Zhejiang University...RecruitingNephrotic Syndrome in Children | TelitaciceptChina
-
RemeGen Co., Ltd.TerminatedIgA NephropathyUnited States
-
RemeGen Co., Ltd.Recruiting
-
RemeGen Co., Ltd.RecruitingSystemic Lupus ErythematosusUnited States, Colombia, Bulgaria, Poland, Puerto Rico, Argentina, Australia, Chile, Hungary, Spain, Germany, Philippines
-
RenJi HospitalNot yet recruitingSystemic Lupus Erythematosus
-
RemeGen Co., Ltd.RecruitingPrimary Sjogren's SyndromeChina
-
RemeGen Co., Ltd.RecruitingSystemic Lupus ErythematosusChina
-
Second Affiliated Hospital, School of Medicine,...Not yet recruiting
-
RemeGen Co., Ltd.Recruiting